

CONSORTIUM CHRONICLE

NEWSLETTER



WellLink | Northeast Ohio Opioid Consortium
Health Matters | EDUCATION SERIES

Join Us Online For
**The Primary Practice Physician
Program for Chronic Pain (4PCP):
A Biobehavioral Revolution in Care**

WEBINAR

THURSDAY, APRIL 16 | 12:00P.M. - 1:30P.M. REGISTER NOW

[Register Here](#)

JOIN US THIS THURSDAY! The Primary Practice Physician Program for Chronic Pain (4PCP): A Biobehavioral Revolution in Care

April 16, 2026 12 p.m. - 1:30 p.m.

Join us for the next Opioid Consortium education series webinar, focusing on The Primary Practice Physician Program for Chronic Pain (4PCP.) Featuring Dr. Jeffrey Janata from University Hospitals, this free webinar will provide an overview of the 4PCP framework, and sharing the tools to implement it.

[Learn More](#) | [View Flyer](#)

State / Local Updates

['Operation Smoke & Mirrors': Dozens arrested in multi-agency drug bust targeting Cleveland's Clark-Fulton area](#)

A months-long, multi-agency drug investigation targeting trafficking networks in the Clark-Fulton neighborhood has led to dozens of arrests and the seizure of narcotics and firearms, the [Cleveland](#) Division of Police announced on March 20. The operation, dubbed "Operation Smoke & Mirrors," was launched in fall 2025 by Cleveland police in partnership with regional and federal law enforcement agencies, including the Ohio High Intensity Drug Trafficking Area initiative.

Investigators focused on the distribution of fentanyl, cocaine and methamphetamine in the Clark-Fulton area, conducting months of surveillance, search warrants and interviews across multiple jurisdictions. Working with the Cuyahoga County Prosecutor's Office, authorities secured indictments against 40 people. On March 19, law enforcement agencies arrested 33 of those suspects in coordinated raids across several cities, including Cleveland, Euclid, Maple Heights, Bedford Heights and Dayton.

Governor DeWine Announces Nearly \$5 Million to Combat Drug Trafficking, Prevent Substance Use Disorder

Ohio Governor Mike DeWine recently announced that two state programs will award a total of \$5 million in funding to support local law enforcement's work to combat illegal drug activity and promote substance use prevention and recovery. The funding is being awarded through Governor DeWine's RecoveryOhio Law Enforcement Fund and the Ohio Drug Law Enforcement Fund. [Click here to read the full media announcement](#)

Mental Health & Addiction Conference Attendee Registration - Now Live – June 1-2, 2026



Attendee registration is now open for Ohio's 2026 Mental Health and Addiction Conference: *Inspiring a Stronger Tomorrow* on June 1-2, 2026 at the Hyatt Regency in downtown Columbus, OH.

In partnership with the Ohio Department of Behavioral Health, the Ohio Department of Rehabilitation & Correction, and the Ohio Department of Health, OACBHA is pleased to build on the successes of our prior conferences and further expand our focus on the full continuum of mental health and addiction

issues. This 16th annual, two-day conference will focus on efforts related to mental health and addiction prevention, education, intervention, treatment, recovery, family supports, community engagement, and more. The conference will help advance the resources and knowledge essential for communities to provide support to those in need. If you have questions about the conference, please contact Shelby Stutzman at sstutzman@oacbha.org. [Click here to learn more and register to attend](#)

Report: U.S. opioid deaths fell 32% in 2024, Ohio sees even steeper drop

Opioid overdose deaths in the U.S. fell sharply from 2023 to 2024, driven largely by decreases in deaths involving fentanyl, and Ohio's drop was even steeper, according to a new national report (Source: "[Opioid deaths dropped in 2024, and Ohio's decline was even steeper: report](#)" Cleveland Plain Dealer, March 18).

Nationally, the total number of deaths dropped about 32% from about 79,000 in 2023 to 54,000 in 2024, according to the new [report from KFF](#). Ohio saw deaths fall about 45% from nearly 4,000 in 2023 to about 2,200 in 2024, KFF said. The state's opioid overdose death rate was 20.1 per 100,000 population in 2024. West Virginia had the highest rate (38.6 per 100,000) among U.S. states in 2024. Nebraska had the lowest rate at 3.3 per 100,000 population.

New Tool for Ohio Behavioral Health Workforce Exploration

With support from an Ohio Department of Behavioral Health grant, the Regional Behavioral Health Workforce Coalitions (RBHWC) and the Mental Health and Addiction Advocacy Coalition (MHAC) launched a new web-based tool aimed at strengthening Ohio's behavioral health workforce. BHEACON is a centralized, interactive platform that guides students, professionals, and career seekers through behavioral health career pathways, licensing requirements, and Ohio-based training programs.

BHEACON is designed for users at every stage of their career — from those just exploring the field to seasoned professionals considering their next step. The site highlights the full spectrum of opportunities in behavioral health, from entry-level positions to roles requiring advanced education, licensure, or certification. [Click here to access BHEACON \(Behavioral Health Education & Career Opportunities Navigator\)](#)

SPOTLIGHTING KEY OBSERVANCES

- **Minority Health Month:** Since 1989, Ohio has celebrated [Minority Health Month](#) in April. The 30-day, high-visibility wellness campaign is designed to promote inclusion, disease prevention, and healthy lifestyles.
- **Recognizing the Role of Counselors in Recovery: [Counseling Awareness Month](#),** observed in April, highlights the critical role counselors play in addressing mental health and substance use disorders. These professionals are often on the front lines, helping individuals navigate recovery, build coping skills, and access critical services.
- **Preventing Prescription Drug Misuse:** April 25 is National Rx Drug Take Back Day. Find a [location near you](#) to safely dispose of unused medications and help prevent misuse.
- **Promoting Mental Health and Recovery:** May is Mental Health Awareness Month, an observance that highlights the strong connection between mental health and substance use disorders. Raising awareness helps reduce stigma and encourages individuals to seek support.

Strengthening Prevention Efforts Nationwide: [National Prevention Week](#)— May 10 through May 16—promotes strategies that prevent substance misuse and support mental health before challenges escalate. Community-based prevention efforts are key to building healthier, more resilient populations.

LOCAL SPOTLIGHT

Ohio Deflection Association

Lunch & Learn Regional Trainings

-Northeast Ohio-

Join us in Summit County for the Northeast, Ohio ODA Regional
“Lunch & Learn” Training

- **Regional workgroup session led by the Regional Representative**
- **Take part in open discussions about funding and program needs**
- **Training on Ohio’s Community Alert Notification System (OCANS)**
- **Regional Drug Trends & Kratom Update – ONIC Staff**

WHERE?

Summit County Public Health

1867 W Market St, Akron, OH 44313

WHEN?

April 29, 2026

10am-2pm

RSVP tom@ohiodeflectionassociation.org

Policy & News Updates

[Medetomidine in the U.S. Illegal Fentanyl Supply Increasing Risk for Overdose and Severe Withdrawal Syndrome](#)

The Centers for Disease Control and Prevention (CDC), in conjunction with the White House Office of National Drug Control Policy (ONDCP), is issuing this Health Advisory to notify public health professionals, clinicians, laboratorians, and people at risk for overdose about

increasing reports from U.S. jurisdictions detecting medetomidine in the illegal drug supply and a severe withdrawal syndrome due to medetomidine exposure.

House Energy and Commerce Committee Focused on Illicit Drug Threats

On Thursday March 26, the House Energy and Commerce Health Subcommittee held a hearing entitled, *Policies to Protect Our Communities from Illicit Drug Threats* as Congress continues to look for ways to restrict access to lethal and dangerous substances in order to protect lives, strengthen public safety, and prevent further harm to families and communities nationwide. The hearing focused on the following fourteen bills:

- [H.R. 1266](#), Combatting Illicit Xylazine Act (Reps. Panetta and Pfluger)
- [H.R. 5630](#), To amend the Public Health Service Act to require additional information in State plans for Substance Use Prevention, Treatment, and Recovery Services block grants (Rep. Houchin)
- [H.R. 5629](#), To provide that the final rule of the Department of Health and Human Services titled “Medications for the Treatment of Opioid Use Disorder”, except for the portion of the final rule relating to accreditation of opioid treatment programs, shall have no force or effect. (Rep. Houchin)
- [H.R. 2004](#), Tyler’s Law (Reps. Lieu and Latta)
- [H.R. 7970](#), STOP Nitazenes Act (Rep. Latta)
- [H.R. 8000](#), END 7-OH Act (Rep. Bilirakis)
- [H.R. 7184](#), PRESS Act (Rep. McDowell)
- [H.R. 8005](#), Stop Pills That Kill Act (Rep. Evans)
- [H.R. 5880](#), Fight Illicit Pill Presses Act (Reps. Hageman and Stansbury)
- [H.R. 1227](#), Alternatives to Pain Act (Reps. Miller-Meeks and Barragan)
- [H.R. 2715](#), Destruction of Hazardous Imports Act (Reps. Higgins and Carter)
- [H.R. 1561](#), ALERT Communities Act (Reps. Crockett and Gooden)
- [H.R. 7994](#), HERO Act (Rep. Ruiz)
- [H.R. 7407](#), Prohibiting Tianeptine and Other Dangerous Products Act of 2026 (Rep. Pallone)

Combatting Illicit Xylazine Act

House lawmakers weighed legislation that aims to stop the spread of xylazine, also known as "tranq," an FDA-approved animal tranquilizer increasingly contaminating the illicit drug supply. Led by Reps. [Jimmy Panetta](#) (D-CA) and [August Pfluger](#) (R-TX), the Combating Illicit

Xylazine Act would classify xylazine as a Schedule III substance under the Controlled Substances Act, allowing the Drug Enforcement Administration to more aggressively target illegal trafficking of the substance while preserving its legal use in veterinary medicine and agriculture.

A [Senate version of the bill](#) from Sen. Catherine Cortez Masto (D-NV) and Sen. Chuck Grassley (R-IA) cleared the chamber's Judiciary Committee in March and now awaits a floor vote. Momentum for the bill comes as xylazine is increasingly being mixed with other drugs, such as fentanyl. The combination offers an enhanced high. Xylazine is a non-opioid sedative, and its effects cannot be reversed by naloxone, an opioid overdose reversal drug. As a result, the xylazine-fentanyl combination is more deadly than fentanyl alone and also associated with developing necrotic skin wounds that can rot human flesh.

Preliminary data from the Centers for Disease Control and Prevention predicts 71,542 drug overdose deaths for the 12 months ending in October 2025 — reflecting a [17.1 percent decline in U.S. overdose deaths](#) compared to the previous year. The dip aligns with an ongoing drop in overdose deaths nationwide, though the decline is starting to flatten. The agency also reported that between 2023 and 2024 the drug overdose death rate involving synthetic opioids — which includes fentanyl — other than methadone [decreased by 35.6 percent](#).

During the hearing, Republicans and Democrats also expressed interest in legislation that would shore up routine fentanyl testing during emergency room visits and expand access to more non-opioid pain management alternatives for Medicare patients.

Latta Introduces STOP Nitazenes Act to Combat Rising Synthetic Opioid Deaths

On March 18, 2026, Congressman Bob Latta (OH-5) introduced the *Strengthening Tools to Outlaw Poisonous (STOP) Nitazenes Act*, a bill to permanently schedule 2-benzylbenzimidazole opioids, commonly known as nitazenes, as Schedule I controlled substances. Fatal overdoses continue to rise across the United States, and nitazenes, a dangerous class of illicit synthetic opioids, are increasingly contributing to overdose deaths nationwide.

Depending on the chemical formulation, some nitazenes can be up to 800 times more potent than morphine and 40 times more potent than fentanyl. Like other illegal street drugs that are often laced with fentanyl, substances may also contain nitazenes without the user's knowledge. According to Medical Discovery News, up to 2,000 people have died from nitazene-related overdoses since 2019. Without greater awareness and education about these substances, that number is expected to grow. Latta has also championed the HALT

Fentanyl Act, which was [signed into law](#) on July 16, 2025. The law permanently classifies fentanyl-related substances as Schedule I drugs under the Controlled Substances Act.

HR 7994 Introduced in Congress to expand access to opioid overdose reversal drugs in schools

Rep. Raul Ruiz, MD (D-CA) introduced legislation on March 19 to establish a grant program to provide schools with opioid overdose reversal drugs, to direct schools receiving Federal funds to report to certain Federal information systems any distribution of an opioid overdose reversal drug.



- Tell Congress to pass the NOPAIN for Veterans Act (S. 3209/H.R. 4509) and support veterans in their fight against opioid addiction. [Click here.](#)
- Help Medicare patients avoid opioid addiction. Urge Congress to pass the Alternatives to PAIN Act (S. 475/ H.R. 1227). [Click here.](#)



Voices for Opioid Choices - Regulatory Advocacy

On the regulatory front, CMS requested comments on improvements to Medicare Advantage and Medicare Part D plans. Voices participated in the opportunity [commented](#):

- As it related to Medicare Advantage plans, Voices urged CMS to push these plans to follow CMS' lead on making available non-opioids during outpatient surgical procedures. Voices noted that Medicare plans already do this as a result of the NOPAIN Act that went into effect in 2025, but that more could be done to ensure that MA plan participants enjoyed similar access
- With respect to Medicare Part D, Voices urged CMS to do more to limit plans' ability to steer patients towards opioids. Voices noted that plans have great flexibilities afforded to them to manage costs and do so via prescription opioids. By doing so, these plans risks exacerbating the opioid addiction crisis. Instead, Voices urged CMS to promulgate guidance prohibiting utilization management practices regarding non-opioid acute pain products.

New Grant Focuses on Advancing New Payment Models for Opioid Use Disorder Treatment

On April 8, the Foundation for Opioid Response Efforts (FORE) announced a [\\$473,675 grant](#) to [The Brookings Institution](#) to develop performance metrics and new payment models

that health plans and other payers can use to measure the quality of opioid use disorder (OUD) treatment and reward providers for delivering comprehensive, high-value care.

The two-year project, led by the [Center on Health Policy at Brookings](#), aims to fill this gap by developing performance metrics that reflect the range of services and supports needed to achieve positive outcomes in community settings, such as federally qualified health centers, certified community behavioral health clinics, and office-based treatment programs. These metrics will be incorporated into new payment methodologies that managed care plans serving Medicare and Medicaid beneficiaries could use to promote best practices for outreach and follow-up care.

As part of the project, Brookings, together with researchers at [Harvard Medical School](#) and the [Center for Health Care Strategies](#), will offer tools and technical assistance to states interested in designing and implementing new pay-for-performance programs for OUD care. Findings will be shared with policymakers, health systems, and payers through policy briefs, technical reports, and stakeholder convenings to inform sustainable, value-based approaches to OUD treatment nationwide.

Medicaid expansion tied to higher opioid treatment rates

States that adopted Medicaid expansion between 2019 and 2023 saw a 21.1% relative increase in buprenorphine treatment rates — or 28.67 per 100,000 residents — to treat opioid disorder, according to a cross-sectional study published Feb. 18 in [JAMA Network Open](#).

[Join SAMHSA to Discuss the Report on Community-Initiated Care in Behavioral Health: Exploring Funding Mechanisms for Substance Use Disorders](#) - Tuesday, April 21, 2-3 p.m.

ET

SAMHSA's Center for Financing Reform and Innovation (CFRI) is releasing a report and hosting a webinar ***Community-Initiated Care in Behavioral Health: Exploring Funding Mechanisms for Substance Use Disorders***. Increasing behavioral health needs and persistent workforce shortages leave many communities without timely access to substance use disorders (SUD) services. Community-initiated care (CIC) offers a promising strategy to expand support by engaging trained community members and leveraging existing local resources to help mitigate the SUD service gaps. Register [HERE](#).

SAMHSA Releases New Advisory



SAMHSA recently released a new advisory exploring community-driven solutions in behavioral health care desert areas with severe provider shortages and long wait times. The advisory highlights adding more community health workers and peer support specialists as a promising method to improve behavioral health care in these areas. The advisory also includes CCBHCs as an approach for enhancing behavioral health access in care deserts.

Overdose Risk Assessment Tool

The National Council for Mental Wellbeing, in partnership with the Centers for Disease Control and Prevention (CDC), the Ad Council and Shatterproof, is inspiring millions to “Start With Hope” in a national public service advertisement (PSA) campaign. This vital new effort aims to deliver a message of hope to those living with substance use disorders (SUDs), as well as those at risk of developing a SUD, empowering them to start their journeys to wellbeing and recovery by learning about prevention and treatment resources.

This tool is for loved ones and allies to support individuals who may be at risk for overdose. The self-assessment can be discussed with a loved one or ally and includes discussion points and resources to reduce overdose risk. [Click here to download the Overdose Risk Assessment Tool](#)

WellLink Health Alliance Supports Funding for CDC

WellLink Health Alliance joined members of CDC Coalition in urging Congress to include at least \$11.581 billion for CDC’s programs in the FY 2027 Labor, Health and Human Services, Education and Related Agencies appropriations bill and to reject any efforts to dismantle the agency or eliminate any of its essential public health programs. In addition to ensuring a strong public health infrastructure and protecting our communities from public health threats and emergencies, CDC programs are crucial to reducing health care costs.

[American Society of Addiction Medicine updates youth treatment standards - Becker's Behavioral Health](#)

[The American Society of Addiction Medicine has released](#) a new volume of the ASAM Criteria establishing dedicated treatment standards and admission criteria for adolescents and transition-age youths with substance use disorder

Training Opportunities

Pain Management & Opioids: A Pain-Centered Approach (1.5 CE Credits)

This course provides evidence-based education on pain management and opioid use disorder (OUD). It covers the pathophysiology of pain, patient assessment, creating patient-centered pain treatment plans, nonpharmacologic pain management options, and strategies for managing patients on opioid analgesics.

- Recognize the origin(s) and types of pain as they relate to pain management and opioid use disorder (OUD).
- Fully assess persons experiencing pain, including risk for OUD.
- Develop safe and effective pain management plans using nonpharmacologic and pharmacologic (non-opioid or opioid) options.
- Partner with patients to reduce risks when taking opioid therapy.

[ASAM eLearning: Pain Management & Opioids: A Patient-Centered Approach](#)

(Click here to Register)

Save the date! – ORN Complimentary Webinar

Join the ORN Spring 2026 Hot Topics in Addiction Medicine webinar, *Medetomidine Impacts on Clinical Management and Systems of Care*, presented by Michael Lynch, MD, on May 13, 2026 at 5 PM ET. Registration is required. *If you have not registered for one of AOAAM webinars in the past, [please subscribe to AOAAM](#), then login and register for the webinars. [Click Here to Register](#)*

Medetomidine, a highly potent veterinary alpha-2 adrenergic agonist, has recently emerged as a significant adulterant within the U.S. illicit opioid supply. This presentation entitled will review the introduction of medetomidine in the U.S. drug supply, the pharmacology and clinical effects of medetomidine, and the distinguishing features of medetomidine toxicity and withdrawal. We will outline emerging treatment strategies emphasizing early, aggressive alpha-2 agonist therapy; nuanced antiemetic approaches; when and how to escalate to IV

dexmedetomidine; and approaches to concurrent opioid withdrawal management. Participants will gain insight into diagnostic challenges, observation and disposition considerations, and strategies for system-level preparedness.

The ORN Spring 2026 Hot Topics in Addiction Medicine webinars will enhance participants' knowledge and clinical competencies in addressing substance use disorders (SUDs) through emerging research, innovative treatment models, and evidence-based interventions.

Integrating Addiction Medicine with Treatment Courts

Wednesday, May 6, 2026 | 1:00 pm – 5:30 pm ET | Live-Virtual

This 4-hour course is designed for medical providers practicing addiction medicine who interact with treatment courts and the justice system. Clinicians will explore the complexities of treating justice-involved individuals and apply practical strategies through case-based learning to enhance collaboration, advocate for evidence-based care, and improve coordination with community resources.

The target audience for this course includes: physicians, physician assistants, nurses, and nurse practitioners who engage with or seek to better understand treatment court systems. This activity addresses the following ACGME Competencies: Patient Care, Medical Based Knowledge, Practice-Based Learning, Interpersonal and Communication Skills, Professionalism, and Systems-based Practice.

[**Learn More & Register**](#)

WellLink Launches SPEAK Bureau

Substance Use Prevention, Education, Advocacy & Knowledge (SPEAK) Bureau is a collaborative training and technical assistance network facilitated by Northeast Ohio Opioid Consortium. Our mission is to connect organizations across Northeast Ohio with leading local experts to expand knowledge, enhance skills, and improve service delivery on complex and emerging issues in polysubstance use and substance use disorder treatment and recovery. We serve as a centralized resource for organizations seeking customized, expert-led education to better address the challenges of substance use in our community. The types of groups and organizations we hope to connect to this form of education include

hospitals, clinics, social service agencies, nonprofits and more. Access the SPEAKer's Bureau [here](#).



ASAM Practice Pearls features in-depth discussions on addiction prevention, treatment, and recovery. This series explores the latest evidence-based approaches to addiction medicine. Listen to interviews with leading experts as they delve into critical topics and share practical tools you can use to improve patient care and promote public health.

Listen Here - [ASAM Practice Pearls | ASAM Education](#)

The [Ohio Substance Use Disorders Center of Excellence](#) (SUD COE) at Case Western Reserve University's Jack, Joseph, and Morton Mandel School of Applied Social Sciences invites practitioners to deepen their understanding of substance use disorder (SUD) treatment. We are pleased to offer a series of training programs designed to equip professionals with the latest and most effective strategies in SUD treatment. Also, check out the SUD COE website for [free trainings](#) (with CEUs!), as well as a wealth of [other resources](#)"

[Clinical QuickNotes on Substance Use Disorders](#)

The Ohio Substance Use Disorders Center of Excellence (SUD COE) has developed "Clinical QuickNotes on Substance Use Disorders" as a tool to provide busy treatment providers with quick overviews of clinically relevant topics. These QuickNotes are designed to be easily digestible, offering essential information that can be reviewed in just a few minutes. Check out each topic below!

- [Cannabis and Mental Health: Navigating Clinical Realities in Ohio](#)
- [Treating Opioid Use Disorder During Pregnancy and the Postpartum Period](#)
- [Medications for Opioid Use Disorder \(MOUD\) in Adolescents and Young Adults](#)
- [What's Happened with Alcohol Use Disorder?](#)
- [Ohio Medical Board Amends Rules for Medication Treatment of Opioid Use Disorders](#)
- [Responding to Provider Trauma, Grief, and Loss Following Unintentional Lethal Overdose](#)

- [Family Grief and Loss Experiences Following Unintentional Lethal Overdose](#)

The **Opioid Response Network's (ORN)** mission is to reduce overdoses and address opioid and stimulant use disorders, and play a key role in tackling the current epidemic. For more information, go to www.OpioidResponseNetwork.org and learn how you and your organization can make a request for free training and education.

- [Hot Topics - On-Demand - AOAAM Learning Portal](#)



Next Tuesday, April 21 - Join WellLink and the YMCA of Greater Cleveland at the Greater Cleveland Food Bank for an impactful lived-experience event.

In this hands-on simulation, each participant will experience financial hardships and navigate a series of day-to-day challenges such as applying for public benefits, securing housing, accessing transportation, and seeking behavioral health support. Participants will interact with event volunteers who represent various agencies and bureaucracies while simultaneously facing time constraints, misinformation, limited resources, and systemic barriers.

[Register Here](#)



We are one month out from **ConnectNEO 2026!** Join us on May 14 for a day of education and networking.

Plus! We're excited to introduce breakout sessions. We have a dynamic panel on addressing behavioral health in our region, along with many others. Closing out the day will be a Fireside Chat with Cuyahoga County Executive Chris Ronayne that is sure to be an insightful, can't miss discussion. Hope to see you there!

[Register Here](#)

Other Resources

Educational Resources Available from WellLink

- [Igniting Compassion Documentary](#)
- [Igniting Compassion Shorts](#)
- [Opioid Consortium Education](#)
- [Naloxone Toolkit](#)
- [A Clinician's Guide: Dental Consequences of MOUD + Solutions](#)
- [Clinicians Guide: on Xylazine Wound Management](#)
- [A Clinician's Guide: The Intersection of Human Trafficking and Substance Use Disorders](#)
- [NEO Opioid Consortium - Beyond Narcan: Treating Opioid Use Disorder in the Field](#)
- [Opioid Roundtable: Using Collaboration to Address the Opioid Crisis in Northeast Ohio](#)
- [NEO Opioid Consortium Education Series: Effective Communication with Individuals with SUD](#)
- [NEO Opioid Consortium Education Series: Appreciative Approach: From Medical Dominancy to Relational Recovery](#)
- [NEO Opioid Education Series: Demystifying Buprenorphine Treatment in the Outpatient Clinic Setting](#)

- [NEO Opioid Education Series: Harnessing Health IT to Strengthen Opioid Stewardship](#)
- [Previous Issues of The Consortium Chronicle Newsletter](#)
- [NEO Opioid Education Series: The Future of Pain Management: Cutting-Edge, Non-Opioid Solutions](#)
- [NEO Opioid Consortium Education Series - Chronic Pain: Bridging Clinical Insight & Lived Experience](#)
- [NEO Opioid Consortium Education Series: SUD Understanding Addiction, Treatment & Recovery](#)
- [Northeast Ohio Opioid Consortium Education Series: Human Trafficking, SUD, and Emerging Drug Trends](#)
- [Northeast Ohio Opioid Consortium Education Series: Stimulant Use & Heart Health](#)



This newsletter is supported by the CDC OD2A LOCAL Grant to the Cuyahoga County Board of Health.

